Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD)
Abrocitinib stands as a targeted therapy, functioning as an inhibitor of Janus kinase (JAK) 1. This pharmaceutical advancement has been meticulously crafted to address the challenges of moderate to severe atopic dermatitis (AD), a prevalent skin ailment in developed nations. Introduced in 2022, Abro...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Medicine in Drug Discovery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590098623000118 |
| _version_ | 1797449458302058496 |
|---|---|
| author | Daniela Bermeo Grajales Nermala Sewdat Ryan Leo Supratik Kar |
| author_facet | Daniela Bermeo Grajales Nermala Sewdat Ryan Leo Supratik Kar |
| author_sort | Daniela Bermeo Grajales |
| collection | DOAJ |
| description | Abrocitinib stands as a targeted therapy, functioning as an inhibitor of Janus kinase (JAK) 1. This pharmaceutical advancement has been meticulously crafted to address the challenges of moderate to severe atopic dermatitis (AD), a prevalent skin ailment in developed nations. Introduced in 2022, Abrocitinib emerged as a cutting-edge addition to its therapeutic category, gaining approval for utilization within the United States. Diverging from its predecessors in the realm of moderate to severe AD treatment, Abrocitinib distinguishes itself through its heightened specificity. Moreover, its tablet formulation facilitates straightforward administration, offering diverse dosage options. An additional noteworthy feature is its applicability to individuals aged 12 and above, making it an option for alleviating symptoms in this demographic. Within this comprehensive assessment, key aspects such as the biological target of the drug, developmental strategies, mode of operation, pharmacokinetics, pharmacodynamics, clinical trial insights, contraindications, potential interactions with other medications, and adverse reactions are examined. In light of the overarching perspective and available clinical evidence, Abrocitinib emerges as a promising orally bioavailable therapeutic, authorized for treating AD. Notably, it gained its initial approval in Japan for patients aged 12 years and older, marking a significant advancement in the realm of dermatological care. |
| first_indexed | 2024-03-09T14:25:19Z |
| format | Article |
| id | doaj.art-e32f550e1f7f4954b64b31b22571ccb1 |
| institution | Directory Open Access Journal |
| issn | 2590-0986 |
| language | English |
| last_indexed | 2024-03-09T14:25:19Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Medicine in Drug Discovery |
| spelling | doaj.art-e32f550e1f7f4954b64b31b22571ccb12023-11-28T07:26:56ZengElsevierMedicine in Drug Discovery2590-09862023-12-0120100161Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD)Daniela Bermeo Grajales0Nermala Sewdat1Ryan Leo2Supratik Kar3Chemometrics and Molecular Modeling Laboratory, Department of Chemistry, Kean University, 1000 Morris Avenue, Union, NJ 07083, USAChemometrics and Molecular Modeling Laboratory, Department of Chemistry, Kean University, 1000 Morris Avenue, Union, NJ 07083, USAChemometrics and Molecular Modeling Laboratory, Department of Chemistry, Kean University, 1000 Morris Avenue, Union, NJ 07083, USACorresponding author.; Chemometrics and Molecular Modeling Laboratory, Department of Chemistry, Kean University, 1000 Morris Avenue, Union, NJ 07083, USAAbrocitinib stands as a targeted therapy, functioning as an inhibitor of Janus kinase (JAK) 1. This pharmaceutical advancement has been meticulously crafted to address the challenges of moderate to severe atopic dermatitis (AD), a prevalent skin ailment in developed nations. Introduced in 2022, Abrocitinib emerged as a cutting-edge addition to its therapeutic category, gaining approval for utilization within the United States. Diverging from its predecessors in the realm of moderate to severe AD treatment, Abrocitinib distinguishes itself through its heightened specificity. Moreover, its tablet formulation facilitates straightforward administration, offering diverse dosage options. An additional noteworthy feature is its applicability to individuals aged 12 and above, making it an option for alleviating symptoms in this demographic. Within this comprehensive assessment, key aspects such as the biological target of the drug, developmental strategies, mode of operation, pharmacokinetics, pharmacodynamics, clinical trial insights, contraindications, potential interactions with other medications, and adverse reactions are examined. In light of the overarching perspective and available clinical evidence, Abrocitinib emerges as a promising orally bioavailable therapeutic, authorized for treating AD. Notably, it gained its initial approval in Japan for patients aged 12 years and older, marking a significant advancement in the realm of dermatological care.http://www.sciencedirect.com/science/article/pii/S2590098623000118AbrocitinibAtopic dermatitisClinical trialsJAK1PK/PDUS FDA |
| spellingShingle | Daniela Bermeo Grajales Nermala Sewdat Ryan Leo Supratik Kar Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD) Medicine in Drug Discovery Abrocitinib Atopic dermatitis Clinical trials JAK1 PK/PD US FDA |
| title | Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD) |
| title_full | Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD) |
| title_fullStr | Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD) |
| title_full_unstemmed | Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD) |
| title_short | Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD) |
| title_sort | unveiling abrocitinib a thorough examination of the 2022 usfda approved treatment for atopic dermatitis ad |
| topic | Abrocitinib Atopic dermatitis Clinical trials JAK1 PK/PD US FDA |
| url | http://www.sciencedirect.com/science/article/pii/S2590098623000118 |
| work_keys_str_mv | AT danielabermeograjales unveilingabrocitinibathoroughexaminationofthe2022usfdaapprovedtreatmentforatopicdermatitisad AT nermalasewdat unveilingabrocitinibathoroughexaminationofthe2022usfdaapprovedtreatmentforatopicdermatitisad AT ryanleo unveilingabrocitinibathoroughexaminationofthe2022usfdaapprovedtreatmentforatopicdermatitisad AT supratikkar unveilingabrocitinibathoroughexaminationofthe2022usfdaapprovedtreatmentforatopicdermatitisad |